Champions Oncology Inc
NASDAQ:CSBR
Intrinsic Value
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. [ Read More ]
The intrinsic value of one CSBR stock under the Base Case scenario is 6.67 USD. Compared to the current market price of 5.06 USD, Champions Oncology Inc is Undervalued by 24%.
Valuation Backtest
Champions Oncology Inc
Run backtest to discover the historical profit from buying and selling CSBR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Champions Oncology Inc
Current Assets | 13.2m |
Cash & Short-Term Investments | 4.5m |
Receivables | 7.9m |
Other Current Assets | 835k |
Non-Current Assets | 13.6m |
PP&E | 13.1m |
Intangibles | 335k |
Other Non-Current Assets | 185k |
Current Liabilities | 22m |
Accounts Payable | 4.8m |
Accrued Liabilities | 3.7m |
Other Current Liabilities | 13.5m |
Non-Current Liabilities | 6.9m |
Other Non-Current Liabilities | 6.9m |
Earnings Waterfall
Champions Oncology Inc
Revenue
|
49.2m
USD
|
Cost of Revenue
|
-29.5m
USD
|
Gross Profit
|
19.7m
USD
|
Operating Expenses
|
-29.3m
USD
|
Operating Income
|
-9.6m
USD
|
Other Expenses
|
-129k
USD
|
Net Income
|
-9.7m
USD
|
Free Cash Flow Analysis
Champions Oncology Inc
CSBR Profitability Score
Profitability Due Diligence
Champions Oncology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Champions Oncology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CSBR Solvency Score
Solvency Due Diligence
Champions Oncology Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Champions Oncology Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CSBR Price Targets Summary
Champions Oncology Inc
According to Wall Street analysts, the average 1-year price target for CSBR is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.
Ownership
CSBR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CSBR Price
Champions Oncology Inc
Average Annual Return | -11.31% |
Standard Deviation of Annual Returns | 33.58% |
Max Drawdown | -73% |
Market Capitalization | 68.8m USD |
Shares Outstanding | 13 593 800 |
Percentage of Shares Shorted | 0.84% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.
Contact
IPO
Employees
Officers
The intrinsic value of one CSBR stock under the Base Case scenario is 6.67 USD.
Compared to the current market price of 5.06 USD, Champions Oncology Inc is Undervalued by 24%.